SK pharmteco, a contract development and manufacturing organization (CDMO), announced significant $260 million investment to expand its small molecule and peptide production capabilities with the construction of a new, cutting-edge facility in Sejong, South Korea.
Set to begin operations in late 2026, this will be the company’s fifth plant in South Korea, serving as a key component of SK pharmteco’s global manufacturing network.
The facility, spanning 1,35,800 square feet, will feature eight production trains with an annual output of tens of metric tons. Additionally, the investment includes state-of-the-art peptide research and development facilities, cGMP kilo labs, and a cGMP pilot plant to support flexible early-stage clinical and commercial peptide production.
As reported by biopharmaapac.com, the expansion also lays the groundwork for a sixth plant, providing the company with the ability to swiftly scale up capacity in the future.
“This expansion underscores our strong commitment to meeting the evolving demands of the life sciences industry,” said Joerg Ahlgrimm, CEO, SK pharmteco.
Ahlgrimm added, “By investing in this new facility, we are boosting our capacity in Asia as part of our global growth strategy, cementing our position as a reliable partner for companies developing cutting-edge treatments and showcasing our ability to adapt in a rapidly shifting industry”.
The investment highlights the company’s dedication to meeting the rising demand for high-quality peptides and small molecules, crucial components of many innovative therapies.
As the life sciences industry experiences rapid expansion, driven by technological advancements and the demand for new treatments, the global supply chain faces challenges such as limited manufacturing capacity and complex regulatory hurdles. SK pharmteco’s new facility aims to address these issues by offering scalable and dependable production solutions for these essential therapies.
“This new facility represents a major investment in our future and our commitment to providing exceptional value to our clients,” said Yongwoo Park, President of SK pharmteco’s Small Molecule division in Asia.
Park added, “With this expansion, we can offer faster turnaround times, increased flexibility, and higher quality standards. This investment further strengthens SK pharmteco’s reputation as a trusted partner in developing innovative cell and gene therapies and small molecules, helping to accelerate the development and commercialization of life-changing treatments”.
